Tumors that lack expression of ER, PR, or HER2 are referred to as ‘triple-negative’ breast cancers, and are irresponsive to hormonal or anti-HER2 therapies that have proven effective against receptor-positive cancers. This evidence concerns the gene PGR and breast carcinoma.